Menero Med

Tadalafil, the active ingredient in Menero Med, is a Phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It is prescribed to treat erectile dysfunction and is also used in the management of benign prostatic hyperplasia and pulmonary arterial hypertension in adult males.

GNH USA supplies Menero Med as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation to facilitate import and distribution.

Tadalafil is a PDE5 inhibitor indicated for several urological and cardiovascular conditions. - Erectile dysfunction: Improves the ability to achieve and maintain an erection sufficient for sexual activity in men with this condition. - Benign prostatic hyperplasia: Relieves lower urinary tract symptoms associated with prostate enlargement, improving urinary flow. - Pulmonary arterial hypertension: Enhances exercise capacity by promoting pulmonary vasodilation and reducing vascular resistance.

Tadalafil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache. - Flushing: warmth and redness of the face or neck. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than 4 hours, requiring medical attention. - Sudden vision loss: non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: abrupt decrease in hearing acuity.

When prescribing tadalafil, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate for recent myocardial infarction or unstable angina before use. - Concomitant nitrates: avoid use with nitrate medications due to risk of severe hypotension. - Visual disorders: monitor patients with pre‑existing retinal disease for changes. - Renal or hepatic impairment: adjust therapy based on severity of organ dysfunction. - Drug interactions: review all concomitant medicines for potential CYP3A4 interactions. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Tadalafil interacts with several drug classes; interactions are classified by their clinical significance.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): combined use can cause dangerous drops in blood pressure. - Alpha‑blockers (e.g., doxazosin) in patients with cardiovascular disease: may lead to severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase tadalafil plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy of tadalafil. - Antihypertensive agents: may enhance blood pressure‑lowering effects. - Other PDE5 inhibitors: concurrent use can increase risk of adverse events.